IABP as a Bridge to Transplantation: Can we Identify Who May Benefit From a LVAD?

被引：0
|
作者：
Guha, A. [1 ]
Ali, A. [1 ]
Nguyen, D. [1 ]
Bruckner, B. [1 ]
Trachtenberg, B. [1 ]
Graviss, E. A. [1 ]
Bhimaraj, A. [1 ]
Park, M. H. [1 ]
Hussain, I. [1 ]
Suarez, E. E. [1 ]
Torre-Amione, G. [1 ]
Estep, J. [1 ]
机构：
[1] Houston Methodist Hosp, Methodist DeBakey Heart Ctr, Houston, TX USA
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2018年 / 37卷 / 04期
关键词：
D O I：
10.1016/j.healun.2018.01.667
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
664
引用
收藏
页码：S267 / S267
页数：1
相关论文
共 50 条
  • [21] Evaluation of the methods to identify patients who may benefit from PARP inhibitor use
    Lim, Diana
    Ngeow, Joanne
    ENDOCRINE-RELATED CANCER, 2016, 23 (06) : R267 - R285
  • [22] What we eat may determine who we can be
    Oski, FA
    NUTRITION, 1997, 13 (03) : 220 - 221
  • [23] How to Identify Cardiac Amyloidosis Patients Who Might Benefit From Cardiac Transplantation
    Ambardekar, Amrut V.
    Fontana, Marianna
    Maurer, Mathew S.
    Trachtenberg, Barry
    Kittleson, Michelle
    JACC-HEART FAILURE, 2023, 11 (01) : 115 - 120
  • [24] VGKC AUTOIMMUNITY: ARE WE MISSING PATIENTS WHO CAN BENEFIT FROM IMMUNOTHERAPY?
    Umemura, Yoshie
    Ronan, Lara
    NEURO-ONCOLOGY, 2013, 15 : 35 - 35
  • [25] HOW CAN WE INCREASE THE PROPORTION OF PATIENTS WHO BENEFIT FROM THROMBOLYSIS
    MATHEY, DG
    SCHOFER, J
    BECHER, H
    HINRICHS, A
    SHEEHAN, F
    BLEIFELD, W
    EUROPEAN HEART JOURNAL, 1985, 6 : 229 - 233
  • [26] A practical tool to identify patients who may benefit from a palliative approach: The CARING criteria
    Fischer, Stacy M.
    Gozansky, Wendolyn S.
    Sauaia, Angela
    Min, Sung-Joon
    Kutner, Jean S.
    Kramer, Andrew
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2006, 31 (04) : 285 - 292
  • [27] Estradiol level may identify postmenopausal women who benefit most from raloxifene.
    Cummings, SR
    Duong, T
    Krueger, KA
    Cauley, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 : S197 - S197
  • [28] How can we identify HCV genotype 1 patients who may benefit from an extended treatment duration with peginterferon α-2a (40kD) plus RBV?
    Sanchez-Tapias, J. M.
    Ferenci, R.
    Diago, M.
    Romero-Gomez, M.
    Zeuzem, S.
    Berg, T.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S242 - S242
  • [29] Comparative Cost Analysis of LVAD vs. Axillary Intraaortic Balloon Pump (IABP) as a Bridge to Transplantation - A Single Center Experience
    Estep, Jerry D.
    Cordero-Reyes, Andrea M.
    Bhimaraj, Arvind
    Loza, Laurie P.
    Loebe, Matthias
    Torre-Amione, Guillermo
    JOURNAL OF CARDIAC FAILURE, 2012, 18 (08) : S100 - S101
  • [30] WHO CAN BENEFIT FROM JIT? .
    Crago, Ken
    Welding and Metal Fabrication, 1988, 56 (04): : 186 - 188
12345